This site is intended for a US audience Non-US Residents For Patients and Caregivers

Patients with Inoperable CTEPH

In a 2011 registry of 679 CTEPH patients, 37% (247) were deemed inoperable1

According to the Fifth World Symposium on Pulmonary Hypertension that convened in 20132:

  • All patients diagnosed with CTEPH should receive lifelong anticoagulation

  • Comparing radiographic burden of disease with hemodynamics is critical to determining operability and risk from surgery before performing pulmonary thromboendarterectomy (PTE) (also called pulmonary endarterectomy [PEA])

  • Overall operability assessment must consider patient factors, including comorbidities

noperable CTEPH patients table

Operability assessment remains a subjective process, so reevaluation of operability by a second experienced CTEPH center in cases initially deemed inoperable is recommended.2

Nonsurgical Treatment of CTEPH

Hear about the ways to treat CTEPH when surgery is not an option.

Compensated by Bayer for video.

Learn about treating recurrent CTEPH

References:

1. Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124(18):1973-1981. 2. Kim NH, Delcroix M, Jenkins DP, et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol. 2013;62(suppl D):D92-D99.

BAYER and the Bayer Cross are registered trademarks of Bayer. All other trademarks are property of their respective owners. These trademark owners are not affiliated with Bayer and do not sponsor or endorse Bayer.

 

Site last modified 09/2023

© 2023 Bayer. All rights reserved.